$1.580
+0.095 (+6.04%)終値時点
- 高値
- 1.660
- 始値
- 1.510
- 出来高加重平均価格
- 1.57
- 出来高
- 55.74K
- 時価総額
- —
- 安値
- 1.460
- 売買代金
- 87.32K
- EV/EBITDA(TTM)
- -2.85
BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol.
AI分析 of BioHarvest Sciences Inc (BHST)
中立Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.
バリュエーション指標
イベントタイムライン
ニュース
2.005-27NASDAQ.COMBioHarvest (BHST) Q4 2025 Earnings Transcript
9.505-14seekingalphaBioHarvest Sciences Q1 2026 Earnings Call Insights
9.505-14seekingalphaBioHarvest Sciences Reports Q1 Financial Results
7.505-13Yahoo FinanceBioHarvest Advances CDMO Program to Stage 2 with $1.125M Agreement
5.004-29seekingalphaBioHarvest Sciences Leadership Transition
BHST のよくある質問 — Alphio AI が回答
BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol. It operates in the Healthcare sector.
Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。